Boeing shares surge as FAA eases restrictions — why the stock can go even higher

The S&P 500 rose 0.2% after August's PCE data showed core inflation met economists' expectations, prompting market buying following a three-day decline. Boeing shares surged nearly 4% as the FAA eased 737 Max delivery restrictions, which is anticipated to accelerate manufacturing, deliveries, and enhance free cash flow. Concurrently, Eli Lilly and Bristol-Myers Squibb saw slight gains, benefiting from an exemption to new 100% pharmaceutical tariffs due to their U.S. manufacturing investments.

Analysis

The market demonstrated a modest risk-on sentiment, with the S&P 500 rising 0.2% following the release of the August personal consumption expenditures (PCE) price index. The core inflation reading, which aligned with economists' expectations, was sufficient to halt a three-day market decline, suggesting investors are sensitive to any data confirming a potential moderation in inflation. On a micro level, Boeing (BA) shares experienced a significant rally, surging nearly 4% on news that the Federal Aviation Administration (FAA) will ease restrictions on 737 Max deliveries. This regulatory development is a critical catalyst, as it allows Boeing to regain authority over final safety checks, which is expected to directly accelerate manufacturing and, most importantly, improve free cash flow generation—a key metric for the company's valuation. Concurrently, in the pharmaceutical sector, Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) are positioned to benefit from a new trade policy. Both companies are exempt from a newly announced 100% tariff on branded pharma products due to their investments in U.S.-based manufacturing plants, providing them with a notable competitive advantage and insulating them from significant tariff-related margin pressure affecting other industry players.

Key Decisions for Investors

• Investors should view the FAA's decision as a significant de-risking event for Boeing, as the expected acceleration in deliveries and free cash flow could justify a re-evaluation of the stock's target price.
• For Eli Lilly and Bristol-Myers Squibb, the exemption from new 100% pharmaceutical tariffs provides a defensive moat against trade policy risk, warranting consideration of these names as potentially more stable holdings within the sector compared to non-exempt peers.
• While the in-line inflation data provided a near-term floor for the market, its non-impactful nature suggests investors should monitor upcoming macroeconomic indicators to confirm a sustained positive trend rather than viewing this as a definitive turning point.